Aceclidine/tropicamide - Presbyopia Therapies

Drug Profile

Aceclidine/tropicamide - Presbyopia Therapies

Alternative Names: PRX 100; Tropicamide/aceclidine

Latest Information Update: 01 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Presbyopia Therapies
  • Class Azabicyclo compounds; Eye disorder therapies; Pyridines
  • Mechanism of Action Adrenergic receptor agonists; Cholinergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Presbyopia

Most Recent Events

  • 30 Jul 2018 Efficacy and safety data from a phase IIb trial in Presbyopia released by Presbyopia Therapies (NCT03201562)
  • 30 Apr 2017 Presbyopia Therapies initiates enrolment in a phase II trial for Presbyopia in USA (NCT03201562)
  • 01 Nov 2015 Presbyopia Therapies completes a phase II trial in Presbyopia in USA (NCT02554396)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top